De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Project Sage Oldco Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Project Sage Oldco.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	17.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Jul 06

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Apr 16

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Jan 06

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Project Sage Oldco onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:SIEN.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2023	90	-59	-14	-11	N/A
6/30/2023	93	-59	-14	-11	N/A
3/31/2023	92	-68	-27	-23	N/A
12/31/2022	91	-73	-38	-35	N/A
9/30/2022	88	-67	-48	-47	N/A
6/30/2022	85	-24	-61	-58	N/A
3/31/2022	84	-24	-51	-48	N/A
12/31/2021	81	-63	-47	-42	N/A
9/30/2021	76	-67	-43	-37	N/A
6/30/2021	72	-97	-34	-29	N/A
3/31/2021	61	-110	-50	-46	N/A
12/31/2020	55	-67	-64	-60	N/A
9/30/2020	60	-67	-70	-66	N/A
6/30/2020	67	-88	-89	-85	N/A
3/31/2020	79	-94	-94	-90	N/A
12/31/2019	46	-58	-90	-87	N/A
9/30/2019	80	-111	-92	-88	N/A
6/30/2019	74	-109	-76	-74	N/A
3/31/2019	71	-90	-69	-68	N/A
12/31/2018	68	-83	-57	-56	N/A
9/30/2018	60	-76	-53	-52	N/A
6/30/2018	53	-70	-62	-61	N/A
3/31/2018	44	-72	-52	-50	N/A
12/31/2017	37	-64	-48	-46	N/A
9/30/2017	32	-54	-44	-43	N/A
6/30/2017	29	-50	N/A	-31	N/A
3/31/2017	27	-40	N/A	-30	N/A
12/31/2016	21	-40	N/A	-34	N/A
9/30/2016	16	-60	N/A	-38	N/A
6/30/2016	19	-57	N/A	-31	N/A
3/31/2016	27	-50	N/A	-28	N/A
12/31/2015	38	-41	N/A	-18	N/A
9/30/2015	49	-16	N/A	-9	N/A
6/30/2015	49	-11	N/A	-8	N/A
3/31/2015	47	-8	N/A	-2	N/A
12/31/2014	45	-6	N/A	0	N/A
9/30/2014	42	-6	N/A	-6	N/A
6/30/2014	39	-11	N/A	-12	N/A
3/31/2014	37	-16	N/A	-22	N/A
12/31/2013	35	-19	N/A	-26	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if SIEN.Q's forecast earnings growth is above the savings rate (2.4%).

Winst versus markt: Insufficient data to determine if SIEN.Q's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if SIEN.Q's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if SIEN.Q's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if SIEN.Q's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if SIEN.Q's Return on Equity is forecast to be high in 3 years time

Project Sage Oldco Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 15%

Sientra, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Sientra, Inc. Revises Earnings Guidance for the Full Year 2023

Sientra, Inc. Provides Earnings Guidance for the Full Year of 2023

Price target decreased to US$2.08

Sientra, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Recent updates

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc.(OTCPK:SIEN.Q) dropped from NASDAQ Composite Index

DIP Financing Approved for Sientra, Inc.

Motion for Asset Sale Filed by Sientra, Inc.

Sientra, Inc. Filed for Bankruptcy

Sientra, Inc. Filed for Bankruptcy

Sientra Receives Non-Compliance Notice from Nasdaq

Consensus EPS estimates fall by 15%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Sientra, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Sientra, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sientra, Inc. Appoints Alexander W. Casdin to the Company’s Board of Directors, Effective June 15, 2023

Sientra Announces FDA-Clearance of Next Generation Allox2 Pro Tissue Expander

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. Provides Earnings Guidance for the Full Year of 2023

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Full year 2022 earnings: EPS misses analyst expectations

Sientra, Inc. Announces Launch of Viality, Novel Fat Transfer System

Insider recently bought US$933k worth of stock

Price target decreased to US$2.08

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sientra, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sientra, Inc. has completed a Follow-on Equity Offering in the amount of $29.217384 million.

Sientra slides 18% on proposes stock offering

Sientra, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra Receives Written Notice from the Listing Qualifications Department of Nasdaq

Sientra Receives Regulatory Approval to Market Breast Implants in Saudi Arabia

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Sientra, Inc. Revises Revenue Guidance for the Year 2022

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

Sientra, Inc. to Report Q2, 2022 Results on Aug 11, 2022

FDA Approves Sientra’s Low Plus Profile Projection Breast Implant

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Sientra, Inc.(NasdaqGS:SIEN) dropped from Russell 2000 Dynamic Index

Price target decreased to US$6.33

Sientra, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.83

Sientra, Inc. to Report Q1, 2022 Results on May 12, 2022

Sientra, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$7.67

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Consensus EPS estimates fall by 31%

Price target decreased to US$10.60

Sientra, Inc. Provides Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.097 loss per share (vs US$0.12 loss in 3Q 2020)

Lead Independent Director Nicholas Simon has left the company

Sientra, Inc. Increases Earnings Guidance for the Full Year 2021

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.68 loss in 2Q 2020)

1315 Capital, LLC completed the acquisition of miraDry business of Sientra, Inc. (NasdaqGS:SIEN).

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven